All In Biotech

Drug Trial Radar · NCT07509086

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Jul 15, 2028

Study completion Jul 15, 2029

Sponsor

Lead sponsor
The First Hospital of Jilin UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.

Conditions

  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia (PCL)

Interventions

  • IL-15-armored CAR-T cellsBiological

    BCMA-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; CD19/BCMA dual-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; GPRC5D-targeted: 1.0/2.0/3.0 × 10\^6 CAR-T cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: From infusion to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.